fbpx Skip to main content

Member's Profile

Neurgain Technologies

8601 Via Mallorca Unit C
La Jolla,   California
United States
Membership Info
Membership Type: Industry
Membership Since: 2020
Need to make an update to your Member Profile or have a question? Contact us here: [email protected]
About Neurgain Technologies
Biotech Company
Neurgain Technologies (NGT) has novel preclinical-proven, patented gene therapy technology and delivery devices to treat chronic neuropathic pain and spinal spasticity. 7-8% of the population suffers from Neuropathic Pain. Current therapeutic management is not working: Drugs in use have poor efficacy, and cause undesirable side effects such as resistance, addiction and other disorders. NGT’s mission is to positively impact this problem by means of our patented innovation to provide a therapy that works and improves the patient’s quality of life. NGT’s solution has potential to positively impact the opioid overdose epidemic.

The Company is developing two assets: 1. Subpial gene delivery platform (device), 2. Pre-clinical gene therapy for severe neuropathic pain. NGT plans to license the platform delivery technologies to multiple pharma/biotech which are developing gene therapy in CNS, it is developing the pain program to the point of completing a First in Human study in patients.
Related News
No related news posted by this Member